Meturix 5 mg Tablets – Summary of Product Characteristics (SmPC) for healthcare professionals

1 NAME OF THE MEDICINAL PRODUCT

Meturix 5 mg Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 5 mg metolazone.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Tablet.

Blue, round biconvex tablets approximately 6 mm in diameter.

The tablet can be divided into equal halves.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Meturix is indicated for the treatment of:

• Oedema related to kidney diseases, including nephrotic syndrome and states of impaired renal function.
• Oedema related to congestive heart failure.
• Oedema related to ascites due to cirrhosis of the liver.

Meturix is also indicated for the treatment of mild to moderate hypertension, alone or in combination with other antihypertensive medicines of a different class (with or without oedema).

4.2 Posology and method of administration

Important note: The bioavailability of Meturix Tablets may be different from other metolazone preparations (see section 5.2). Therefore, the recommended doses (expressed in mg) can differ from other metolazone products. A dose adjustment may be necessary and individualised titration based on patient’s response and tolerability is advised if switching from Meturix tablets to another metolazone product or vice versa.

Posology

Adults

Treatment of Oedema

Metolazone should generally be administered once daily.

The tablet should always be taken at the same time in relation to food.

The following dosages should serve as guidelines:

• Oedema (renal): 5 to 20 mg once daily.
• Oedema (cardiac): 5 to 10 mg once daily.
• Oedema (hepatic) and ascites due to cirrhosis of the liver: 5 to 20 mg once daily.

The therapy should be initiated with a dose of 5 mg/day and the dose must be adjusted according to the individual response of the patient. Once the desired therapeutic effect has been achieved, it may be advisable to reduce the maintenance dose if possible.

In some cases (for cardiac and renal oedema), 2.5 mg or 5 mg administered daily or on alternate days can be considered for maintenance therapy.

Doses greater than 20 mg (20-80 mg) have been used in patients with refractory oedema. These dosages require careful monitoring. However, no more than 80 mg should be given in any 24-hour period.

Hypertension: 2.5 to 5 mg once daily.

The recommended initial dose in mild and moderate hypertension is 2.5 mg/day, and the dose must be adjusted according to the individual response of the patient. Once the desired therapeutic effect has been achieved, it may be advisable to reduce the maintenance dose.

In some cases, 2.5 mg or 5 mg administered daily or on alternate days, can be considered for maintenance therapy.

Renal impairment

Metolazone should be used with caution in patients with severe impaired renal function. If azotemia and oliguria deteriorate during treatment of patients with severe renal disease, metolazone should be discontinued. (See section 4.3 and 4.4).

Hepatic impairment

Metolazone should be used with caution in patients with severe impaired hepatic function (see section 4.3 and 4.4).

Patient with electrolyte disturbances

Metolazone should be used with caution in patients with pre-existing electrolyte disturbances. Careful monitoring of the fluid and electrolyte balance is required (see section 4.3 and 4.4).

Elderly

Metolazone should be used with caution in elderly patients.

Paediatric population

The safety and efficacy of Meturix in children aged under 18 years has not yet been established. No data are available.

4.3 Contraindications

• Hypersensitivity to the active substance, sulfonamides, thiazides or to any of the excipients listed in section 6.1.
• Anuria.
• Hepatic coma or precomatose conditions.
• Severe disturbances of the electrolyte balance.

4.4 Special warnings and precautions for use

Renal impairment

Metolazone should be used with caution in patients with severe renal impairment. Renal function should be regularly monitored during thiazide therapy.

Hepatic impairment

In severe hepatic impairment, hypokalaemia caused by diuretics can precipitate encephalopathy.

Electrolyte imbalance

Fluid and electrolyte balance should be carefully monitored during treatment with Meturix, especially if used concurrently with medicines also affecting electrolyte balance such as other diuretics (risk of hypokalaemia), corticosteroids, ACE-inhibitors, angiotensin-II-antagonists and aldosterone antagonists.

All patients receiving metolazone should have serum electrolytes measured at regular intervals and be observed for clinical signs of fluid and/or electrolyte imbalance; namely, hypokalaemia, hyponatraemia, hypochloraemic alkalosis. Serum and urine electrolyte measurements are particularly important when the patient is vomiting excessively, has severe diarrhoea, or is receiving parenteral fluids.

Warning signs of electrolyte imbalance irrespective of cause are: dryness of mouth; thirst; weakness; lethargy; drowsiness; restlessness; muscle pains or cramps; muscular fatigue; hypotension; oliguria; tachycardia and gastrointestinal disturbances such as nausea and vomiting.

The risk of hypokalaemia is increased when larger metolazone doses are used, when diuresis is rapid, when severe liver disease is present, when corticosteroids are given concomitantly, when oral intake is inadequate or when excess potassium is being lost extra renally such as with vomiting or diarrhoea. Hypokalaemia should be corrected by the addition of potassium-sparing diuretics, potassium supplements or potassium containing salts substitutes to the regimen. Hyperkalaemia may also occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended.

Hyponatraemia may occur at any time during long term therapy and, on rare occasions, may be life threatening.

Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism.

Thiazides should be discontinued before carrying out tests for parathyroid function.

Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.

Primary adrenal insufficiency

Diuretics should be avoided for the treatment of hypertension if the patient has primary adrenal insufficiency, known as Addison’s disease.

Concurrent treatment with other drugs

Special care is advised, especially during initial therapy, when metolazone is used with other antihypertensive drugs of a different class to avoid hypotension (see section 4.5).

Orthostatic hypotension associated with diuretics may be enhanced by alcohol, barbiturates and opioids.

Particular caution is also required when metolazone is used in combination with ACE inhibitors, angiotensin-II-antagonists, aldosterone-antagonists and/or NSAIDs since there have been cases of renal failure, mostly due to enhanced dehydration. Dose adjustments may be required.

Concomitant use of metolazone and furosemide may lead to unusually large or prolonged losses of fluid and electrolytes.

Gout attacks

Azotemia and hyperuricemia may occur during the administration of thiazide therapy. Infrequently, attacks of gout have been reported in persons with a history of gout.

Choroidal effusion, acute myopia and secondary angle-closure glaucoma Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma.

Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled.

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

Lupus erythematosus

Sulfonamide derivatives have been reported to exacerbate or activate systemic lupus erythematosus.

Porphyria

Although not reported with Meturix, thiazides have been associated with acute attacks of porphyria. Caution is required when Meturix is used in porphyric patients.

Glucose metabolism

Meturix has only a slight effect on the glucose metabolism.

Meturix may increase the blood sugar level, which in patients with diabetes mellitus or latent diabetes mellitus may lead to hyperglycaemia and glycosuria. Therefore, blood sugar levels should be checked on a regular basis. In diabetic patients the antidiabetic treatment may have to be adjusted.

Laboratory values

Although not reported with metolazone, thiazides and thiazide-like diuretics have been reported to adversely effect the plasma lipid profile by increasing VLDL or LDL-cholesterol and triglycerides. The clinical relevance of these observations is unclear.

4.5 Interaction with other medicinal products and other forms of interaction

No formal interaction studies have been performed with Meturix.

Loop Diuretics (e.g. furosemide)

Concurrent use of furosemide and presumably also of other loop diuretics may potentiate the effect of metolazone considerably and lead to serious disturbances of the electrolyte balance (see section 4.4).

Curariform Drugs

Diuretic-induced hypokalaemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine). The most serious effect would be respiratory depression which could proceed to apnoea. Accordingly, it is advisable to discontinue metolazone tablets three days before elective surgery.

Ciclosporin

Concurrent administration of metolazone and ciclosporin may lead to an increase in serum creatinine.

Alcohol, barbiturates and narcotics

Alcohol, barbiturates and narcotics may potentiate orthostatic hypotension which may occur during treatment with metolazone.

Antidiabetic medicinal products (oral agents and insulins)

Dosage adjustment of the antidiabetic medicinal product may be required (see section 4.4).

Corticosteroids and ACTH

Corticosteroids and ACTH may increase the risk of hypokalaemia and increase salt and water retention.

Cardiac Glycosides

Hypokalaemia may increase the risk of digitalis toxicity with higher risk of severe arrhythmias. In case of concurrent administration with digitalis drugs the dosage may need to be adjusted (see section 4.4.).

Antiarrhythmic drugs (e.g. Sotalol)

Hypokalaemia associated with thiazide therapy may increase the risk of sotalol induced arrhythmia (syncope, prolonged QT interval).

Non-steroidal anti-inflammatory drugs (NSAIDs)

The administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics. As with other diuretics, metolazone may increase the risk of nephrotoxicity of NSAIDs and lead to deterioration of renal function.

Sympathomimetics

May decrease the antihypertensive effect of metolazone. Metolazone may decrease arterial responsiveness to norepinephrine, but this effect is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

Antigout medicinal products

Dosage adjustments of antigout medicinal products may be necessary as thiazide diuretics may raise the level of serum uric acid (see section 4.4).

Increase in dosage of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics may increase the incidence of hypersensitivity reactions to allopurinol.

Calcium salts

Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly.

Lithium

Concurrent use of lithium and thiazides may reduce lithium clearance leading to intoxication.

Other antihypertensive drugs

Concomitant administration of metolazone and other antihypertensive drugs may result in hypotension. Particular caution is required in the initial phase. Dosage adjustments of other antihypertensives may be necessary.

Meturix may be co-administered with potassium-sparing diuretics when indicated. In such cases, frequent determination of serum potassium is recommended, and potassium supplements should be avoided (see section 4.4).

Cross-reactivity with other drugs

Cross reactions may occur in patients who are allergic to sulfonamides or thiazides.

Anticoagulants

Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; dosage adjustments may be necessary.

Methenamine

Efficacy may be decreased due to urinary alkalizing effect of metolazone.

4.6 Fertility, pregnancy and lactation

Pregnancy

Thiazide diuretics and related diuretics may pass over to the foetus and cause electrolyte imbalance. Cases of neonatal thrombocytopenia have been reported.

Therefore, metolazone must not be administered during the last trimester of pregnancy unless necessary, and then with the lowest recommended dose.

Breast-feeding

Metolazone passes over to the breast milk in such an amount that there is a risk for the baby child even at therapeutic doses. Inhibition of lactation has been observed in treatment with diuretics.

4.7 Effects on ability to drive and use machines

Metolazone may cause adverse reactions affecting the ability to drive a vehicle and/or to operate machines, such as dizziness and fatigue.

4.8 Undesirable effects

Within each System Organ Class, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (> 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, < 1/100); rare (≥ 1/10,000, < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).

Description of selected adverse reactions:

Cases of choroidal effusion with visual field defect have been reported after the use of thiazide and thiazide-like diuretics.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms: Overdosing may lead to dehydration and electrolyte disturbances (primarily hyponatremia, but also loss of potassium and magnesium), and as a consequence the patient may experience thirst, nausea, vomiting, disorientation, somnolence, headache, muscle cramps, arterial hypotension, and in severe cases dysrhythmia (hypokalaemia).

Treatment: Within the first hour of ingestion the absorption may be reduced by administration of medicinal charcoal (1 g/kg body weight). Thereafter priority should be given to establish adequate hydration and re- establishment of the electrolyte balance.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Sulfonamides, plain; ATC code: C03BA08

Mechanism of action

Metolazone obstructs the re-absorption of sodium in the ascending branch of the loop of Henle and in the proximal tubules, which leads to excretion of approximately equivalent amounts of sodium and chloride.

At the optimal therapeutic dosage metolazone leads to approximately the same diuretic activity as diuretic of the thiazide-type. However, it may also stimulate the diuresis in patients with a very low glomerular filtration rate (less than 20 ml/min).

Diuresis starts within the first hour after administration and will continue for 12- 24 hours depending on the dose. The maximum effect will be achieved after approximately 2 hours.

5.2 Pharmacokinetic properties

Other metolazone products may have different bioavailability when compared to Meturix and in some cases it may be up to 2-fold higher (see section 4.2). Therefore, once the appropriate dose has been identified for a patient with a certain product, this product cannot readily be exchange with another product.

Absorption

The rate and extent of metolazone absorption are formulation dependent.

The effect of concomitant food on the bioavailability of Meturix has not been evaluated.

In order, to minimise variability for the individual patient, the tablet should always be taken at the same time in relation to food (see section 4.2).

Distribution

Meturix binds extensively to plasma proteins and erythrocytes.

Metolazone crosses the placenta and passes into breast milk.

Metabolism and Elimination

Meturix has an enterohepatic circulation, and this explains its long half-life, i.e. its prolonged therapeutic effect (12 to 24 hours, depending on the dose administered, and may in high doses exceed at 24 hours).

In case of impaired kidney function, the excretion is delayed, as the clearance of metolazone is directly related to renal function (creatinine clearance).

5.3 Preclinical safety data

No data is available.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Microcrystalline cellulose

Magnesium stearate

Indigo carmine (E132)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

4 years

6.4 Special precautions for storage

Store in the original package in order to protect from light.

Keep the blister in the outer carton

6.5 Nature and contents of container

PVC / Aluminium blisters in packs of 20 or 40 tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7 MARKETING AUTHORISATION HOLDER

ALTURiX Ltd

287 Upper Fourth Street

Milton Keynes

MK9 1EH

United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 44490/0010

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

10/09/2026

10 DATE OF REVISION OF THE TEXT

10/09/2026